Gali R R, Pugazhenthi S, Khandelwal R L
Department of Biochemistry, University of Saskatchewan, Saskatoon, Canada.
Metabolism. 1993 Nov;42(11):1475-80. doi: 10.1016/0026-0495(93)90201-x.
The effects of the protein kinase C inhibitors staurosporine and H-7 [1-(5-isoquinolinylsulfonyl)-2-methylpiperazine] on glucose-induced regulation of glycogen synthase and phosphorylase activities were investigated in the primary culture of hepatocytes. Glycogen synthesis as measured by the incorporation of [14C]glucose into glycogen was enhanced up to 78% (P < .001) by 100 nmol/L staurosporine. In contrast, H-7 inhibited glycogen synthesis in a dose-dependent manner, with an IC50 value of 70 mumol/L. Activation of glycogen synthase by 30 mmol/L glucose was enhanced significantly (P < .02 and less) by staurosporine at 20 nmol/L and higher concentrations whereas the activity of this enzyme was inhibited by H-7 (IC50 = 50 mumol/L). The inactivation of phosphorylase by glucose was significantly greater when staurosporine was included in the medium. However, H-7 increased the phosphorylase activity ratio by 1.5- to 2.5-fold at concentrations of 20 to 100 mumol/L. The time course of synthase activation and phosphorylase inactivation showed that the effect of glucose was enhanced by staurosporine and inhibited by H-7. These novel reciprocal effects of protein kinase C inhibitors were also observed at different concentrations of glucose. The effects of H-8, a compound with structural resemblance to H-7 and an inhibitor of protein kinase A, were similar to those of staurosporine but not to those of H-7. Staurosporine blocked the effects of vasopressin and 4 beta-phorbol 12 beta-myristate 13 alpha-acetate (PMA), whereas H-7 in combination with these protein kinase C activators acted in the same direction. The effects of staurosporine, a relatively more specific inhibitor of protein kinase C, indicated that this enzyme plays a role in the regulation of glycogen metabolism in liver. However, H-7, which is known to have protein kinase C-independent effects in intact cells, seems to alter the activities of glycogen synthase and phosphorylase by a different mechanism.
在肝细胞原代培养中,研究了蛋白激酶C抑制剂星形孢菌素和H-7 [1-(5-异喹啉磺酰基)-2-甲基哌嗪] 对葡萄糖诱导的糖原合酶和磷酸化酶活性调节的影响。通过将[14C]葡萄糖掺入糖原中测量的糖原合成,在100 nmol/L星形孢菌素作用下增强了78%(P <.001)。相比之下,H-7以剂量依赖性方式抑制糖原合成,IC50值为70 μmol/L。20 nmol/L及更高浓度的星形孢菌素显著增强(P <.02及更低)30 mmol/L葡萄糖对糖原合酶的激活作用,而该酶的活性被H-7抑制(IC50 = 50 μmol/L)。当培养基中加入星形孢菌素时,葡萄糖对磷酸化酶的失活作用显著增强。然而,H-7在20至100 μmol/L浓度下使磷酸化酶活性比值增加了1.5至2.5倍。合酶激活和磷酸化酶失活的时间进程表明,星形孢菌素增强了葡萄糖的作用,而H-7抑制了葡萄糖的作用。在不同浓度的葡萄糖下也观察到了蛋白激酶C抑制剂的这些新的相反作用。与H-7结构相似且为蛋白激酶A抑制剂的H-8的作用与星形孢菌素相似,但与H-7不同。星形孢菌素阻断了血管加压素和4β-佛波醇12β-肉豆蔻酸酯13α-乙酸酯(PMA)的作用,而H-7与这些蛋白激酶C激活剂联合作用时作用方向相同。蛋白激酶C相对更特异性的抑制剂星形孢菌素的作用表明,该酶在肝脏糖原代谢调节中起作用。然而,已知在完整细胞中具有蛋白激酶C非依赖性作用的H-7似乎通过不同机制改变糖原合酶和磷酸化酶的活性。